- Home
- XNCR vs VCEL Comparison
XNCR vs VCEL Comparison
Compare XNCR & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XNCR | VCEL |
|---|---|---|
| Founded | 1997 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | 2013 | 1996 |
Fundamental Metrics
Financial Performance| Metric | XNCR | VCEL |
|---|---|---|
| Price | $23.51 | $40.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $22.33 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 1.3M | 439.6K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.36 | 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | $125,576,000.00 | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | $4.80 | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 13.65 | ★ 16.45 |
| 52 Week Low | $8.49 | $28.95 |
| 52 Week High | $30.61 | $49.32 |
Technical Indicators
Market Signals| Indicator | XNCR | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 49.04 | 40.84 |
| Support Level | $11.20 | $35.45 |
| Resistance Level | $30.61 | $41.25 |
| Average True Range (ATR) | 1.45 | 1.17 |
| MACD | -0.70 | -0.17 |
| Stochastic Oscillator | 9.93 | 40.51 |
Price Performance
Historical ComparisonAbout XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.